36 results about "Gastro-" patented technology

The invention discloses a gastric retention double-layer sustained-release tablet and a preparation method and application thereof, and belongs to the field of pharmaceutical preparations, the active ingredient of the gastric retention double-layer sustained-release tablet is 3-[4-[4-(lH-benzotriazole-1-yl) butyl] piperazine-1-yl] benzisothiazole hydrochloride, and the gastric retention double-layer sustained-release tablet is composed of a quick-release drug release layer and a sustained-release drug release layer, the quick release layer contains an active component, a filler I and a disintegrating agent; and the sustained-release layer contains an active component, a filler II, an expansion material, a release retardant, an expansion accelerator and a stabilizer. According to the gastro-retention double-layer sustained-release tablet, the quick-release layer can quickly release the medicine to reach the effective blood concentration, and the retention time of the tablet in the stomach is prolonged after the sustained-release layer expands, so that the in-vivo absorption window of the medicine is prolonged, the maintenance of the blood concentration is realized, the in-vivo half-life period of active ingredients is remarkably prolonged, the administration frequency can be reduced, and the compliance of a patient is improved. The product is simple in preparation process, suitable for industrial production and wide in development prospect.

The present disclosure relates to an apparatus and a method for a laser treatment of gastro-esophageal reflux disease using a balloon catheter.

A gastro-resistant high-strength unit dosage form includes a solid solution prepared by hot-melt extrusion, whereby the solid solution contains 300 mg posaconazole and an enteric polymer in a specific weight ratio. The unit dosage form may be a capsule or an optionally film-coated tablet.

The invention relates to floating drug delivery systems (FDDS) that provide solutions to the particular problems often encountered with floating drug delivery systems described in the art. On such generally recognized problem is the vulnerability of the systems, especially damage to the gas-filled compartment making it accessible to water so as to impair its buoyancy, ultimately resulting in insufficient gastric residence time. The invention, in an aspect, provides a self-repairing FDDS that maintains its floating capacity after damaging. The floating drug delivery systems of the invention, furthermore, allow for incorporation of high loads of active ingredients. The floating drug delivery systems can be designed in such a way that release of active ingredient from the system occurs entirely independent from the pH of the fluid surrounding the system. Furthermore, the procedure of manufacturing the floating drug delivery system of the invention is simple and straightforward, and therefore economically attractive.

An orally administrable drug powder composition which forms a gastro-retentive RAFT having at least two trigger pulses is provided. The composition contains, at a minimum, (a) at least one drug in an immediate release pulse release form; (b) at least one drug in a delayed trigger release form; (c) at least one non-toxic gas generating agent and (d) a RAFT system, wherein following oral ingestion, the composition provides a self-assembling gastro-retentive RAFT having entrapped therein, the at least one drug of (a) and (b) and the gas generated in situ by the non-toxic gas generating agent, thereby providing a floating gastro-retentive RAFT having a dual pulse system wherein at least the second pulse is a trigger pulse and which retains the at least one drug in the stomach for at least about 3 hours, provided that the composition does not include a gamma hydroxybutyrate and its salts, hydrates, tautomers, or solvates, or complexes thereof.

The invention is directed to a delivery device (10) for introducing and / or deploying an implant (12, 107) within the gastro-intestinal tract. The implant may be a bypass sleeve. The delivery device comprises a shaft assembly (24) with a longitudinal axis (L) and has an atraumatic tip component (26, 102) arranged at a distal end of the shaft assembly (24).

The invention relates to a predictive gene expression signature of response to antiangiogenic drugs, such as axitinib, in gastro-enteric-pancreatic and pulmonary neuroendocrine tumours. The signature is formed by the gene expression of three genes (SPP1, ATXN7 and REXO1L2P), which is converted by means of a bioinformation packet into a unique score that can predict which patients will benefit from treatment with the drug, this benefit being understood as longer survival without progression and larger tumour volume reductions in response to treatment.

The purpose of the present invention is to provide a novel composition for promoting the secretion of galactotropin. According to the present invention, provided is a composition for promoting secretion of gastro-somatotropin, which contains, as an active ingredient, one or more substances selected from the group consisting of oleic acid and acylglycerols containing palmitic acid and / or oleic acid as constituent fatty acids. The composition is preferably a composition for promoting appetite, improving inappetence, promoting secretion of growth hormone, improving low nutrition, promoting fat accumulation, increasing body weight, enhancing gastric acid secretion or enhancing gastric motility. The composition is preferably a food composition.

The present application relates to the technical field of veterinary medicine preparation, and particularly relates to a water-soluble medicine gastro-resistant and enteric-coated granule, a preparation method and application thereof, the coated granule comprising: an inner core of at least one water-soluble medicine active ingredient, a coating layer coated outside the inner core; and the coating layer is formed by a composite coating material of hydrogenated palm oil and lipophilic hydrophobic nano active light calcium carbonate. The present application has the advantages that the nano calcium carbonate is used to form pores in the true stomach by acid reaction and to produce gas by saponification with fatty acids in the intestinal tract, so that the water-soluble medicine is efficiently protected in the rumen and rapidly and completely released in the intestinal tract. In vitro tests show that the effective release rate can reach more than 79%, which is significantly better than the traditional coating, and has a broad clinical application prospect.

The present invention provides NOS inhibitors such as iNOS inhibitors including alkylamine or heteroalkylamine derivatives, or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, hydrate, or isomer thereof, in any crystalline form or in amorphous form. Pharmaceutical products comprising the NOS inhibitors such as iNOS inhibitors and the applications thereof in prophylaxis and / or treatment of inflammatory diseases, and proliferative diseases such as cancer including gastro-intestinal, colorectal, gynecological, pancreatic, head and neck, esophageal, breast, lung, and central nervous system tumors, among others, are also provided.

The invention relates to an anchor (14) for an implant (20) for use in the gastro-intestinal tract. The anchor (14) comprises a tissue contact portion (16) with a bedding region (16a). The bedding region (16a) is configured to at least partly integrate into, or to promote integration into, a wall of the gastro-intestinal tract.

The present application relates to a kind of amoxicillin gastric retention sustained-release preparation, which contains amoxicillin, sustained-release material, swelling agent and other pharmaceutical adjuvant, preferably also contains stabilizer or ion regulator.The combination of the above-mentioned adjuvant can be retained in the stomach for up to 24 hours, the complete release time is 10-24h, which can significantly prolong the retention time of amoxicillin in the stomach, has the advantages of fast floating, high effective concentration of drug in the stomach, long stable concentration time, and is beneficial to reduce the frequency of drug administration of patients;Further preferably, it is made into a double-layer tablet containing immediate-release layer, which can quickly reach effective concentration and also can be released slowly and continuously, maintaining effective concentration for a long time;When combined with proton pump inhibitors such as vonolabian, etc., combination kit or compound, only 1-2 times per day is needed, which can further improve the therapeutic effect and patient compliance.

This invention discloses an extracellular vesicle derived from Gastrodia elata, its preparation method, and its use in preparing drugs for treating glaucoma, belonging to the field of biomedical technology. This invention claims protection for an extracellular vesicle prepared from dried Gastrodia elata. The extracellular vesicles provided by this invention have no significant cytotoxicity and good biocompatibility. Studies have shown that these extracellular vesicles can significantly inhibit apoptosis of R28 cells and loss of Brn3a⁺ cells in the mouse retina in a glutamate excitotoxicity model. In a glaucoma model, these extracellular vesicles can effectively protect the survival of retinal ganglion cells (RGCs) and retinal function, and can significantly reduce retinal neuroinflammatory responses in the glaucoma model. Therefore, the extracellular vesicles provided by this invention have a clear anti-glaucoma-related retinal damage effect and possess great potential for development into drugs for treating glaucoma.

One or more devices, systems, methods, and storage mediums for performing robotic control, correction, adjustment, and / or smoothing for a continuum robot are provided herein. Examples of such control, correction, adjustment, and / or smoothing include, but are not limited to, correction of one or more sections or portions of a continuum robot as the continuum robot is moved, state transition(s) or change(s), and path smoothing for a continuum robot. Examples of applications include imaging, evaluating, and diagnosing biological objects, such as, but not limited to, for Gastro-intestinal, cardio, bronchial, and / or ophthalmic applications, and being obtained via one or more optical instruments, such as, but not limited to, optical probes, catheters, endoscopes, and bronchoscopes. Techniques provided herein also improve processing and imaging efficiency while achieving images that are more precise, and also achieve devices, systems, methods, and storage mediums that reduce mental and physical burden and improve ease of use.

The invention discloses a traction capsule stomach tube and a using method thereof, and the traction capsule stomach tube comprises an instant capsule shell which is made of water-soluble food-grade gelatin and can be dissolved in the stomach; a thin hole is formed in the near end side of the instant capsule shell; a channel with two open ends is formed in the film stomach tube; a plurality of side holes are formed in the far-end side of the thin-film stomach tube in a staggered mode, and a cutting line is arranged on the near-end side of the thin-film stomach tube. The thin-film stomach tube can be coiled and folded; the guide ball head wraps the far-end side of the thin-film stomach tube and enables the far-end side opening of the thin-film stomach tube to be kept in an open state; the guide ball head is made of a water-soluble hard candy ball and can be dissolved in the stomach, and the dissolving time of the guide ball head is longer than that of the instant capsule shell; the prompter is arranged on the near-end side of the thin-film stomach tube, and the position where the thin-film stomach tube reaches is prompted through color changes generated by the acid-base reaction.

This description relates to gastro-resistant controlled-release dosage forms comprising Compound (I): (see Formula) (I), or a pharmaceutically acceptable salt and / or solvate thereof, the pharmacokinetic properties of these dosage forms, and their preparation. The novel dosage forms described herein are useful for reducing the risk of QT prolongation in a subject and for treating a disorder in a subject in need, e.g., a subject diagnosed with schizophrenia, for example, in the treatment of negative symptoms in a subject diagnosed with schizophrenia who has the CYP2D6 EM genotype.

The present invention relates to a gastro resistant capsule comprising one or more proteases. wherein the capsule shell comprises a water-soluble film forming polymer and a water-soluble enteric polymer. The present invention also relates to methods of manufacturing the gastro resistant capsules and uses thereof.

The present invention provides non-invasive intraoral devices and methods for the detection of intraoral acid exposure, methods of making said devices, and their use in the diagnosis of disorders such as gastro-oesophageal reflux disease (GORD).

A gastro-resistant nutraceutical composition is described, comprising a pomace extract (preferably of the Aglianico cultivar), rich in polyphenols, microencapsulated in maltodextrins (MaGPE), preferably in combination with vitamin B2, vitamin A and zinc, and the use thereof to counteract age-related macular degeneration.

The invention relates to a predictive gene expression signature of response to antiangiogenic drugs, such as axitinib, in gastro-enteric-pancreatic and pulmonary neuroendocrine tumours. The signature is formed by the gene expression of three genes (SPP1, ATXN7 and REXO1L2P), which is converted by means of a bioinformation packet into a unique score that can predict which patients will benefit from treatment with the drug, this benefit being understood as longer survival without progression and larger tumour volume reductions in response to treatment.

The invention relates to the field of biological medicine, in particular to a CD66c-targeted antibody coupling medicine and application thereof in preparation of a medicine for treating gastroesophageal junction cancer, the structure of the antibody coupling medicine is shown as follows: Ab-(L-D) n, Ab is an anti-CD66c antibody, the anti-CD66c antibody is selected from a full-length antibody or an antibody fragment, L is a connexon, n is a positive integer, and n is a positive integer. The linker is selected from a non-breakable linker or a breakable linker; d is a cell toxic agent, the cell toxic agent is selected from toxins, chemotherapeutics, antibiotics, radioisotopes or growth inhibitors, and n is an integer from 1 to 40. The CD66c is found to be a novel gastro-esophageal junction cancer ADC target spot, meanwhile, the synthesized CD66c-DXd ADC is proved to have a remarkable killing effect on the gastro-esophageal junction cancer at the in-vivo and in-vitro levels, and a promising targeted therapy candidate drug is provided for targeted therapy of the gastro-esophageal junction cancer.

Provided herein are controlled release gastroretentive dosage forms containing deuterated tetrabenazine for use in the treatment of e.g. Hyperactivity dyskinesia. The dosage form provides advantageous pharmacokinetic profiles when orally administered to a subject once a day.

This invention relates to the field of intelligent medical device technology, specifically to an intelligent health patch system and its control method based on gastro-brain axis communication. The system includes an intelligent patch integrating a multimodal physiological sensing module for collecting gastric electrical signals and heart rate variability signals, and a biomimetic control execution module for performing transcutaneous electrical stimulation and tactile feedback; a mobile computing terminal configured with a gastro-brain axis state assessment model for evaluating the user's hunger drive level based on the physiological signals, and a personalized control decision engine for generating control instructions. The mobile computing terminal can, based on the output of the assessment model, achieve non-invasive closed-loop control of the gastro-brain axis: for the first time, closed-loop management of "ascending signal sensing" and "descending neural control" of the gastro-brain axis is realized on a consumer-grade wearable patch, making the intervention more physiologically targeted and scientific.

The present invention relates to the use of human milk oligosaccharides for feeding production animals such as calves. The present invention further relates to milk replacer compositions containing human milk oligosaccharides. Further subject matter of the present invention is a method for preventing and treating gastrointestinal diseases, particularly gastro-intestinal infections, of young production animals, in particular calves, by administering an effective amount of one or more human milk oligosaccharides. Particularly useful in the context of the present invention as one or the human milk oligosaccharide is 2'-fucosyllactose (2-FL).

A gastro rectal oscopy system that includes a body portion, a base portion, a vibratory device and an inflatable device. The body portion has a proximal end and a distal end, wherein intermediate the proximal end and the distal end. The body portion has a plurality of elongated openings formed therein. The head portion is attached to the distal end. The head portion has at least one light source mounted therein. The base portion is attached to the proximal end. The base portion has a control provided thereon and a connector. The vibratory device is positioned inside of at least one of the body portion, the head portion and the base portion. The inflatable device is provided inside of the body portion. The inflatable device is positionable in an uninflated configuration and an inflated configuration. When the inflatable device is in the uninflated configuration, the inflatable device does not extend above an outer surface of the body portion. When the inflatable device is in the inflated configuration, the inflatable device extends through the plurality of openings above the outer surface of the body portion. The connector is operably attached to the inflatable device for changing the inflatable device between the uninflated configuration and the inflated configuration.

The application discloses a kind of over gastrointestinal coating materials and preparation method and application thereof, belong to functional coating material and feed additive preparation technical field.The coating material has continuous phase-dispersed phase two-phase structure: continuous phase includes hydrogenated oil, as over stomach barrier and heat-resistant framework;Dispersed phase includes the degradable microsphere with shellac coating on surface, uniformly embedded in continuous phase.Shellac coating has the dual function of protecting anchoring in stomach and dissolving and exposing microsphere in intestinal pH response.After microsphere degrades in intestinal, form spherical cavity in continuous phase in situ and interconnect into through channel network, guide coating film to be fragmented into small fragments along the arrangement direction of microsphere, it is expected to solve the shell film residue problem caused by the disordered dissolution of existing single-phase homogeneous film depending on surfactant.Microsphere and microfibrillated cellulose can form a synergistic framework to enhance the stability of high-temperature form.The coating material simultaneously realizes the organic unity of high-temperature resistance, over stomach protection and intestinal disintegration, and is suitable for coating treatment of tannic acid and other plant polyphenols feed additives.

The invention provides different types of floating composition of diaminophenothiazine (DAPTZ) compounds such as methylene blue, which provide rapid-release in the stomach, or are gastro-retained. They further provide methods of making and using the same in the treatment and / or prevention of diseases. In one embodiment the invention provides an oral pharmaceutical composition which is a film-coated solid tablet comprising a DAPTZ compound as active ingredient in a gastro-retentive platform. In another embodiment the invention provides an oral pharmaceutical composition comprising an elongate hollow cylindrical capsule containing a weighting agent which is retained at one end, the capsule being buoyant and self-orientating, wherein the capsule is coated with an inner sustained release layer comprising a DAPTZ compound as active ingredient, and a further protective outer layer.

One or more devices, systems, methods, and storage mediums for performing self-diagnosis using one or more imaging modalities are provided herein. Examples of applications include imaging, evaluating and diagnosing biological objects, such as, but not limited to, for Gastro-intestinal, cardio and / or ophthalmic applications, and being obtained via one or more optical instruments, such as, but not limited to, optical probes, catheters, capsules and needles (e.g., a biopsy needle). Devices, systems, methods, and storage mediums may include or involve a method, such as, but not limited to, for determining status or health (such as optical health) of a rotary joint of an apparatus / system and / or of the apparatus / system. A device, system, method, or storage medium may perform self-diagnosis or diagnosis to minimize, reduce, and / or avoid optical failures, rotary joint failures, or apparatus / system failures and to have a robust method(s) of determining the health of the rotary joint and / or the apparatus or system.

The invention relates to application of a gastric retention shape memory composite membrane. The gastric retention shape memory composite membrane is prepared by the following method: (1) mixing a polymer with dichloromethane to obtain a solution 1; (2) preparing a solution 2 by taking water as a solvent, wherein the solution 2 contains hydroxypropyl methyl cellulose and NaHCO3; and (3) mixing the solution 1 and the solution 2, stirring, adding the luteolin phospholipid complex, continuously stirring, and volatilizing dichloromethane and water. The gastro-retention shape memory composite membrane provided by the invention can be used for preparing a medicine for treating gastric cancer, has a good in-vivo expansion effect, has the deformation temperature closer to the temperature of a human body, and can enhance the permeation of luteolin to a biological membrane, improve the gastrointestinal absorption effect of luteolin, reduce stomach discomfort of a patient and improve the bioavailability of the medicine.

Gastrointestinal release capsule intended for use in a method for desensitizing and / or making tolerant a subject allergic to peanuts, or alternatively for diagnosing a peanut allergy in a subject, said capsule comprising a shell and a core, said core comprising a peanut composition including peanut, at least one oil, at least one first powdered excipient, and optionally at least one second prebiotic excipient.